Global private equity and venture capital news and research

Posts Tagged ‘Clarus Ventures’

20 October 2015

Biotech VC investors co-lead $102m round in newly-launched Gritstone

bacteria-359956_1920 Life sciences and biotech-focused investors Versant Ventures, The Column Group and Clarus Ventures have co-led a $102m round for Gritstone Oncology, marking the new firm’s launch.

10 June 2015

Clarus closes oversubscribed third fund on $500m

health Clarus Ventures has closed its oversubscribed third life sciences fund on $500m, well above its $375m target.

17 December 2014

Novartis Venture leads $34m round for Annexon Bioscience

test-tubes-1-1416029-m Novartis Venture Funds has led a $34m Series A-1 funding round for neurodegenerative treatment company Annexon Bioscience.

13 November 2014

Trio invest $40m in Flowonix Medical

medical-instruments-3-1033916-m Clarus, Elevage and Hercules have provided a combination of debt and equity financing , totalling $40m, in implantable drug delivery solutions company Flowonix Medical.

5 November 2014

Clarus leads $26.5m round in biotech company Imago BioSciences

lab-751198-m Global venture capital firm Clarus Ventures has led a $26.5m Series A financing round in biotechnology firm Imago BioSciences.

30 October 2014

PE-backed Sientra raises $75m IPO

stock Private equity-backed breast implant seller Sientra has raised $75m for its IPO.

23 September 2014

Clarus unveils new $50m vehicle amid $375m-targeting life science fundraise

syringe-m Clarus Ventures has revealed a new $50m fund vehicle as it continues collecting capital for its latest flagship life sciences fund.

20 June 2014

Clarus Ventures raises more than $200m for third fund

clarus Life sciences-focused venture firm Clarus Ventures has hit the $200m mark for its $375m-targeting third fund, according to a document filed with US securities regulators.

7 February 2014

Clarus Ventures seeks $375m for new life sciences fund $

life science test tube_sq Venture capital firm Clarus Ventures has launched its third life sciences fund with a $375m target, AltAssets has learned.

22 October 2013

Aerie’s venture backers eye strong stake valuations from imminent IPO $

The venture capital-backers of eye disease treatment company Aerie Pharmaceuticals all plan to drop their stakes to below 20 per cent through the company’s impending IPO.

Page 1 of 212

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016